Protocol Ledger

NCT04603495 · Phase III · ACTIVE NOT RECRUITING

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

Interventional Phase III clinical trial protocol NCT04603495 sponsored by Novartis in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-09 Enrollment: 430 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04603495
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)430 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04603495
Protocol FieldVerified Registry Value
NCT IdentifierNCT04603495
Consolidated Lead SponsorNovartis
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment430 participants (ACTUAL)
Registered Start Date2021-04-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI